Xolair (omalizumab) shows superior efficacy and safety compared to multi-allergen oral immunotherapy in treating food ...
Beyond direct costs, CROs incur significant expenses in the pre-award phase, creating strategic proposals to compete for trial contracts from sponsors. These activities, often unpaid, cost millions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback